HHM Wealth Advisors LLC bought a new stake in Pfizer Inc. (NYSE:PFE) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,781 shares of the biopharmaceutical company’s stock, valued at approximately $123,000.

Several other institutional investors also recently modified their holdings of PFE. Orser Capital Management LLC raised its stake in shares of Pfizer by 2.7% in the 4th quarter. Orser Capital Management LLC now owns 10,990 shares of the biopharmaceutical company’s stock valued at $428,000 after purchasing an additional 290 shares in the last quarter. S.E.E.D. Planning Group LLC acquired a new stake in Pfizer during the fourth quarter worth about $479,000. Cornerstone Wealth Group LLC raised its stake in Pfizer by 5.3% during the fourth quarter. Cornerstone Wealth Group LLC now owns 8,696 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 439 shares during the period. American Assets Investment Management LLC raised its stake in Pfizer by 124.6% during the fourth quarter. American Assets Investment Management LLC now owns 128,000 shares of the biopharmaceutical company’s stock worth $5,015,000 after acquiring an additional 71,000 shares during the period. Finally, EFG Asset Management Americas Corp. raised its stake in Pfizer by 161.5% during the fourth quarter. EFG Asset Management Americas Corp. now owns 34,067 shares of the biopharmaceutical company’s stock worth $1,335,000 after acquiring an additional 21,038 shares during the period. Institutional investors and hedge funds own 70.21% of the company’s stock.

Several research firms recently weighed in on PFE. Cantor Fitzgerald reiterated a “buy” rating and set a $53.00 price objective on shares of Pfizer in a research note on Thursday, March 19th. Morgan Stanley dropped their price objective on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 2nd. Royal Bank of Canada restated a “buy” rating and issued a $44.00 price target on shares of Pfizer in a research note on Monday, April 27th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target on the stock. in a research note on Monday, May 4th. Finally, Standpoint Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $41.28.

In related news, SVP Jennifer B. Damico sold 2,181 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $38.35, for a total transaction of $83,641.35. Following the completion of the sale, the senior vice president now directly owns 9,647 shares in the company, valued at $369,962.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Pfizer Inc bought 312,500 shares of Pfizer stock in a transaction that occurred on Monday, March 16th. The shares were acquired at an average price of $16.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here. Company insiders own 0.08% of the company’s stock.

Shares of Pfizer stock traded down $0.45 on Friday, hitting $37.73. The company had a trading volume of 9,093,286 shares, compared to its average volume of 20,551,962. The business has a 50-day simple moving average of $37.01 and a 200-day simple moving average of $36.82. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78. The company has a market cap of $207.81 billion, a PE ratio of 13.51, a PEG ratio of 2.73 and a beta of 0.71. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $44.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.09. The business had revenue of $12.03 billion during the quarter, compared to analysts’ expectations of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The business’s revenue was down 8.3% on a year-over-year basis. During the same period last year, the firm posted $0.85 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 8th will be issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 4.03%. The ex-dividend date of this dividend is Thursday, May 7th. Pfizer’s payout ratio is 51.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Which market index is the best?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.